Real-life management of patients with mild cognitive impairment: an Italian survey

Laura Bonanni1, Annachiara Cagnin2, Claudia Carrarini3,4

  • 1Neurology Clinic, Department of Medicine and Aging Sciences, University G. D'Annunzio of Chieti-Pescara, Chieti, Italy.

Abstract

Insights

Management of mild cognitive impairment (MCI) in Italy is suboptimal due to non-uniform diagnostic and therapeutic strategies. Standardized approaches are urgently needed to improve patient prognosis and care for this heterogeneous condition.

Area of Science:

  • Neurology
  • Geriatrics
  • Clinical Medicine

Background:

  • Mild cognitive impairment (MCI) presents with diverse causes and progression rates.
  • Clinical heterogeneity of MCI leads to varied diagnostic and therapeutic practices.
  • Lack of uniform recommendations hinders optimal MCI patient management and prognosis.

Purpose of the Study:

  • To evaluate the diagnostic and therapeutic strategies for MCI patients in Italian Memory Clinics.
  • To identify variations in clinical management of MCI across different centers.

Main Methods:

  • A two-phase survey was administered to Italian neurologists.
  • Phase 1 explored general clinical management of MCI.
  • Phase 2 assessed real-life diagnostic and therapeutic decisions for MCI patients.

Main Results:

  • 121 neurologists participated in Phase 1; 203 patients in Phase 2.
  • Non-uniform diagnostic criteria and heterogeneous therapeutic strategies were observed.
  • Data confirmed significant variability in MCI management.

Conclusions:

  • Current management of MCI patients in Italy is suboptimal.
  • There is a critical need for standardized diagnostic and therapeutic approaches for MCI.
  • Standardization is essential to improve outcomes for individuals with MCI.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
96
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
244